The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
PRECEDE
1 other identifier
interventional
3,000
1 country
85
Brief Summary
This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) participants , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable cardiovascular-diseases
Started Nov 2025
Shorter than P25 for not_applicable cardiovascular-diseases
85 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 12, 2025
CompletedFirst Posted
Study publicly available on registry
April 4, 2025
CompletedStudy Start
First participant enrolled
November 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 28, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
May 22, 2026
May 1, 2026
11 months
March 12, 2025
May 19, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
The number and percentage of COPD in participants with CVD,CHD,AF,CHF.
To describe the prevalence of COPD in participants with CVD.
Baseline
Secondary Outcomes (18)
The hospitalization/readmission rate in participants with COPD.
Baseline-week12
The hospitalization/readmission rate in CHD, AF and CHF participants with COPD.
Baseline-week12
Change from baseline in SAQ score in participants with CHD and COPD.
Baseline,week4,week8,week12
Change from baseline in AFEQT score in participants with AF and COPD.
Baseline,week4,week8,week12
Change from baseline in KCCQ score in participants with CHF and COPD.
Baseline,week4,week8,week12
- +13 more secondary outcomes
Other Outcomes (12)
The exacerbation rate in CVD, CHD, AF and CHF participants with COPD over 12 weeks.
Baseline-week12
Rate of MACE in CVD, CHD, AF and CHF participants with COPD over 12 weeks.
Baseline-week12
Rate of differente types of MACE in CVD, CHD, AF and CHF participants with COPD over 12 weeks.
Baseline-week12
- +9 more other outcomes
Study Arms (1)
Guideline education and implementation
OTHERInterventions
The intervention is implemented at the investigator level and the patient level, consisted of 3 parts： 1. Disease education * Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled. * Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study. 2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD. 3. Follow-up management:the subjects will be followed up every 4 weeks.
Eligibility Criteria
You may qualify if:
- Give signed written informed consent to participate.
- At least 40 years of age at baseline visit.
- Previous or newly diagnosed by at least one of the 3 types of CVD which are,
- Coronary heart disease ( CHD )
- Atrial fibrillation (AF )
- Chronic heart failure ( CHF )
- Participants can undergo spirometry testing and does not have the following serious diseases or disease states：
- Shock within the last 3 months
- Mycardial infarction, stroke or unstable angina within last 1 month
- Currently suffering from severe HF or severe arrhythmia. Severe HF refers to the need for intravenous administration of vasoactive drugs and diuretics; severe arrhythmia refers to arrhythmias that cause hemodynamic instability, such as ventricular fibrillation and ventricular tachycardia
- Severe hemoptysis or active gastrointestinal bleeding within last 1 month
- Patients with seizures requiring medication
- Patients with hypertensive crisis or uncontrolled hypertension \[systolic blood pressure \> 200 mmHg, diastolic blood pressure \> 100 mmHg (1 mmHg = 0.133 kPa)\]
- Patients with active respiratory infectious diseases or infectious diseases, such as open pulmonary tuberculosis, influenza, new coronavirus infection, and acute pneumonia
- Patients with aortic or cerebral aneurysms
- +4 more criteria
You may not qualify if:
- Significant diseases or conditions, which, in the opinion of the investigator, may put the participant at risk because of participation in the study or may influence either the results of the study or the participant's ability to participate in the study.
- Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
- Participant who are not able to provide written informed consent.
- Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (85)
Research Site
Anqing, 246004, China
Research Site
Beijing, 100029, China
Research Site
Beijing, 100029, China
Research Site
Beijing, 100037, China
Research Site
Beijing, 100050, China
Research Site
Beijing, 100191, China
Research Site
Changsha, 410005, China
Research Site
Changsha, 410300, China
Research Site
Chaohu, 238001, China
Research Site
Chengdu, 610021, China
Research Site
Chengdu, 610041, China
Research Site
Chengdu, 610072, China
Research Site
Chifeng, 024206, China
Research Site
Chongqing, 400010, China
Research Site
Dalian, 116001, China
Research Site
Dingzhou, 562100, China
Research Site
Dongguan, 523009, China
Research Site
Foshan, CN-528000, China
Research Site
Fuyang, 236400, China
Research Site
Fuzhou, 350005, China
Research Site
Ganzhou, 341699, China
Research Site
Guanghan, 618300, China
Research Site
Guangzhou, 510080, China
Research Site
Guangzhou, 510100, China
Research Site
Guangzhou, 510280, China
Research Site
Guangzhou, 510515, China
Research Site
Haikou, 570311, China
Research Site
Hangzhou, 310016, China
Research Site
Hangzhou, 310030, China
Research Site
Harbin, 150001, China
Research Site
Harbin, 150036, China
Research Site
Hefei, 230001, China
Research Site
Hefei, 230011, China
Research Site
Hubei, 434300, China
Research Site
Jinhua, 321099, China
Research Site
Jinzhong, 030600, China
Research Site
Jiujiang, 332000, China
Research Site
Kaiyuan, 661600, China
Research Site
Kunming, 650032, China
Research Site
Kunming, 650101, China
Research Site
Lanzhou, 730000, China
Research Site
Leping, 333300, China
Research Site
Lianjiang, 524400, China
Research Site
Linhai, 317000, China
Research Site
Meizhou, 514031, China
Research Site
Mianyang, 621000, China
Research Site
Nanchang, 330006, China
Research Site
Neijiang, 641200, China
Research Site
Ningbo, 315600, China
Research Site
Ningbo, 315700, China
Research Site
Putian, 351106, China
Research Site
Quanzhou, 362000, China
Research Site
Shanghai, 200072, China
Research Site
Shanghai, 200080, China
Research Site
Shanghai, 201114, China
Research Site
Shanghai, 201199, China
Research Site
Shanghai, 201318, China
Research Site
Shantou, 515031, China
Research Site
Shantou, 515041, China
Research Site
Shenyang, 110004, China
Research Site
Shenzhen, 518036, China
Research Site
Shijiazhuang, 50051, China
Research Site
Sichuan, 643200, China
Research Site
Suining, 629000, China
Research Site
Suzhou, 215300, China
Research Site
Taiyuan, 030001, China
Research Site
Taiyuan, 030032, China
Research Site
Tai’an, 271000, China
Research Site
Tianjin, 300050, China
Research Site
Tianjin, 300211, China
Research Site
Tianjin, 300222, China
Research Site
Tianmen, 431700, China
Research Site
Wuhan, 430000, China
Research Site
Wuhan, 430000, China
Research Site
Wuxi, 214122, China
Research Site
Xi'an, 710100, China
Research Site
Xiamen, 361003, China
Research Site
Xiangyang, 441000, China
Research Site
Xinzheng, 451100, China
Research Site
Xuzhou, 221009, China
Research Site
Yangzhou, 225001, China
Research Site
Yulin, 537000, China
Research Site
Zhangzhou, 363099, China
Research Site
Zhengzhou, 450000, China
Research Site
Zunyi, 563100, China
MeSH Terms
Conditions
Central Study Contacts
AstraZeneca Clinical Study Information Center
CONTACT
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 12, 2025
First Posted
April 4, 2025
Study Start
November 28, 2025
Primary Completion (Estimated)
October 28, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
May 22, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
- Access Criteria
- When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. 'Yes' , indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.